Skip to content

Author

R. Maziarz

We have 4 of 43 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment for patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). One notable complication is immune effector cell-associated neurotoxicity syndrome (ICANS) which can be life-threatening. Treatment includes supportive...

Vivek G. Patel, Shakthi T. Bhaskar, S. Schuster et al. · 0 citations
Open access Jul 2026

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

The results demonstrate the importance of continuous patient monitoring and management during CAR-T therapy and demonstrate an evolving treatment landscape, including more aggressive management of CRS and interest in preventive therapies for CRS and ICANS.

M. Frigault, R. Maziarz, T. Amoloja et al. · 0 citations
Open access Aug 2026

Challenges with expansion of cell and gene therapy: A call for system-level action

The key challenges inherent to CGT expansion are summarized, priority areas for coordinated action are identified, and a call to the field to address these needs with urgency and shared commitment is issued.

Jeffery J. Auletta, Á. Urbano-Ispizua, R. Maziarz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.